1xbet 사기
News Releases
1xbet 사기
2023
1xbet 사기
1xbet 사기uka's U.K. subsidiary Astex Has Third Approval Success in a Drug Discovery Collaboration - AstraZeneca's Truqap™ for the treatment of metastatic breast cancer approved in the U.S.
1xbet 사기
1xbet 사기uka and Astex announce that the European Commission has approved INAQOVI®(oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia
1xbet 사기
Astex Expands Drug Discovery Collaboration With MSD
2022
1xbet 사기
Announcement of Termination of Co-Development and Exclusive MarketingAgreements with Takara Bio for NY-ESO-1・siTCR®gene therapy candidate
1xbet 사기
European Medicines Agency commences review of oral fixed-dosecombination of decitabine and cedazuridine for the treatment ofadults with acute myeloid leukemia
1xbet 사기
Osaka University and 1xbet 사기uka Pharmaceutical to Enter into an Exclusive License Agreement on New Anti-tumor Antibody
1xbet 사기
1xbet 사기uka Subsidiary to Receive Payment and Royalties from Approval in U.S. ofRadioligand Therapy for Metastatic Castration-Resistant Prostate Cancer- Out-licensed by ABX in Germany, an indirectly-owned subsidiary of 1xbet 사기uka Pharmaceutical -
2021
1xbet 사기
1xbet 사기uka and Rebirthel Sign Licensing Agreement for iPSC-derived CAR-T / TCR-T Production Technology
1xbet 사기
Announcement of Termination of Co-Development and Exclusive Marketing Agreements with Takara Bio for Oncolytic virus HF10 and CD19-Targeted CAR Gene Therapies
1xbet 사기
Busulfex Injection 60mg Approved in Japan for Once-daily Administration in Pediatric Patients
2020
1xbet 사기
1xbet 사기uka and its subsidiary Astex announce results of phase 3, ASTRAL-2 and ASTRAL-3 trials of guadecitabine in patients with previously treated AML and MDS/CMML
1xbet 사기
1xbet 사기uka announces simultaneous regulatory approvals by U.S. FDA and Health Canada of INQOVI®, an oral hypomethylating agent (HMA) therapy for MDS and CMML
1xbet 사기
Clinical program for NY-ESO-1/siTCRTMgene therapy candidate receives designation in Japan as Orphan Regenerative Medicine
1xbet 사기
1xbet 사기uka's Busulfex Receives Additional Indication in Japan as a Conditioning regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
2019
1xbet 사기
1xbet 사기uka and Taiho Announce that Taiho Will Commercialize Two of Astex Pharmaceuticals' Drug Candidates in North America
1xbet 사기
1xbet 사기uka and its Subsidiary Astex Pharmaceuticals, Inc. Announce Positive Results from a Phase III Clinical Trial of Anticancer Candidate ASTX727
1xbet 사기
Erdafitinib Receives Regula1xbet 사기ry Approval in U.S.
1xbet 사기
Designation Description Change of NY-ESO-1・siTCRTM gene therapy product under "SAKIGAKE Designation System"
2018
1xbet 사기
Busulfex Injection 60mg Approved in Japan for Once-Daily Administration in Adults
1xbet 사기
1xbet 사기uka and Astex announce results of the phase 3 ASTRAL-1 study of guadecitabine (SGI-110) in treatment-naïve AML patients ineligible to receive intense induction chemotherapy
1xbet 사기
1xbet 사기uka enters agreement with Takara Bio for co-development and sales rights in Japan to NY-ESO-1 siTCRTM and CD19 CAR gene therapies
2017
1xbet 사기
1xbet 사기uka to Invest in Megakaryon Corporation, with the Aim to Advance Commercialization of iPS-cell-derived Platelet Preparations
1xbet 사기
Ribociclib (LEE011) Receives Regula1xbet 사기ry Approval in U.S. as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer with an aromatase inhibi1xbet 사기r
2016
1xbet 사기
1xbet 사기uka Signs Japan-Exclusive License Agreement with Takara Bio for the Investigational Cancer Treatment HF10, an Oncolytic Virus
1xbet 사기
ICLUSIG®Tablets 15 mg Now Available in Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
1xbet 사기
Positive Phase III Clinical Trial Results for Ribociclib (LEE011), an Investigational Compound for Advanced Breast Cancer in Development by Major Pharmaceutical Company under a Research Collaboration with 1xbet 사기uka's Subsidiary Astex Pharmaceuticals
1xbet 사기
ICLUSIG®Tablets 15 mg Approved in Japan for Patients with Chronic Myeloid Leukemia and Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
1xbet 사기
1xbet 사기uka's U.S. Subsidiary Astex Pharmaceuticals Enters Clinical Trial Collaboration to Explore the Potential of Combining Guadecitabine (SGI-110) with Atezolizumab in the Treatment of Acute Myeloid Leukemia
1xbet 사기
1xbet 사기uka and ARIAD Announce New Drug Application for Ponatinib Submitted in Japan for the Treatment of Refractory Leukemia
2014
2012
1xbet 사기
Kyowa Hakko Kirin Returns to 1xbet 사기uka Pharmaceutical the Rights to Develop and Market Busulfex®, for Use As a Part of Conditioning Regimen Prior 1xbet 사기 Hema1xbet 사기poietic Progeni1xbet 사기r Cell Transplantation, in Japan and in Asian Countries & Regions
1xbet 사기
1xbet 사기uka Pharmaceutical and Kyowa Hakko Kirin announce strategic alliance in the fields of diabetes and oncology
2011
1xbet 사기
Anti-cancer agent "Sprycel® 20mg Tablets and Sprycel® 50mg Tablets (dasatinib)" approved as the first-line treatment of chronic myeloid leukemia-A new treatment option for newly-diagnosed CML patients-
1xbet 사기
1xbet 사기uka Announces Initiation of Phase I Clinical Trial for Therapeutic Cancer Vaccine OCV-105
1xbet 사기
1xbet 사기uka Announces Initiation of Phase II Clinical Trials for Angiogenesis Inhibitor OCV-101
2010
1xbet 사기
Starting co-promotion of the anti-cancer agent “SPRYCEL®Tablet 20mg and SPRYCEL®Tablet 50mg” (dasatinib) in Japan
1xbet 사기
The results of a subset analysis of Japanese patients from the DASISION trial comparing SPRYCEL®(dasatinib) with imatinib in the treatment of newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia.
1xbet 사기
Follow-Up Results from Study Comparing SPRYCEL®(dasatinib) 1xbet 사기 Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data*1
1xbet 사기
FDA Approves SPRYCEL®(dasatinib) as Treatment for Adult Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia in Chronic Phase
1xbet 사기
1xbet 사기UKA OPENS FIRST OFFICE IN CANADA Important Milestone for Growing North American Pharmaceutical Operations
1xbet 사기
SPRYCEL®(dasatinib) Receives FDA Priority Review for the Treatment of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase
1xbet 사기
GW and 1xbet 사기uka Agree Three Year Extension to Global Cannabinoid Research Collaboration
1xbet 사기
Four-Year Follow-Up Data for SPRYCEL®(dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®*
1xbet 사기
SPRYCEL®(dasatinib) Demonstrates Superior Confirmed Complete Cy1xbet 사기genetic Response Rates Compared 1xbet 사기 Gleevec®*in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
1xbet 사기